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Vedolizumab Trough Levels in Children With Anti-Tumor
Necrosis Factor Refractory Inflammatory Bowel Disease
Martine A. Aardoom, Maria M.E. Jongsma, yAnnick de Vries, yJasja Wolthoorn,
Lissy de Ridder, and Johanna C. Escher
ABSTRACT
Objectives: Inflammatory bowel disease (IBD) can be successfully treated
with vedolizumab. Studies in adult IBD patients have shown that differences in
response to vedolizumab may be related to variability in vedolizumab trough
levels, but in children with pediatric-onset IBD data regarding vedolizumab
trough levels are not available. Thus far, the role of trough levels in pediatric-
onset IBD treatment remains unclear. We aimed to investigate predictors of
vedolizumab trough levels in pediatric-onset IBD patients.
Methods: Data from anti-tumor necrosis factor refractory pediatric-onset IBD
patients who received vedolizumab were collected retrospectively. Vedolizumab
trough levels were measured in serum samples collected before each infusion. A
linear mixed model was conducted to analyze factors that influence trough levels.
Results: Twenty-six pediatric-onset IBD patients (14 ulcerative colitis [UC]),
9 Crohn Disease [CD], 3 IBD-unclassified [IBD-U]) received 258 vedolizumab
infusions. Mean vedolizumab trough level at week 6 was 29.9 mg/mL (SD 17.8),
and 11.5 mg/mL (SD 4.9) during maintenance therapy. CD patients had
significantly lower trough levels than IBD-U patients (b 15.2; 95%
confidence interval [CI] 1.1 to 29.2; P¼ 0.036). Higher fecal calprotectin
(b0.009; 95% CI0.02 to0.003; P¼ 0.007) and C-reactive protein levels
(b0.4; 95% CI0.72 to0.04; P¼ 0.027) were associated with lower trough
levels, whereas shortening of time between infusions led to higher trough levels
(b 0.77; 95% CI 0.9 to 0.64; P< 0.001).
Conclusions: In this group of pediatric-onset IBD patients, trough levels
were significantly lower in CD patients compared with UC/IBD-U patients.
Higher levels of inflammatory markers were associated with lower
vedolizumab trough levels.
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What Is Known
 Vedolizumab treatment in children with inflamma-
tory bowel disease is safe, but shows variable efficacy.
 In adult patients with inflammatory bowel disease
accumulating evidence indicates an exposure-effi-
cacy relationship for vedolizumab.
What Is New
 Trough levels in pediatric patients with inflammatory
bowel disease are comparable to those in adult
patients with inflammatory bowel disease.
 A pediatric Crohn’s disease diagnosis results in sig-
nificantly lower vedolizumab trough levels when
compared with pediatric patients with ulcerative
colitis or inflammatory bowel disease unclassified.
 Next to diagnosis, low vedolizumab trough levels in
patients with pediatric inflammatory bowel disease
are associated with high levels of fecal calprotectin,
high levels of C-reactive protein, and more days
between infusions.
I n pediatric-onset inflammatory bowel disease (PIBD) patientsthat do not respond to anti-tumor necrosis factor (TNF), vedo-
lizumab (VDZ), a biological agent that is still off-label for pediatric
patients, is recommended (1). VDZ is a monoclonal antibody
directed against a4b7 integrin, which is expressed on a discrete
subset of memory T-helper lymphocytes involved in the intestinal
inflammation that characterizes IBD (2). Since 2014, VDZ is
registered for adult IBD patients after placebo-controlled trials
demonstrated its efficacy in ulcerative colitis (UC) and Crohn
disease (CD) patients above 18 years (2–5). Several cohort studies
in adults have confirmed VDZ effectiveness and have shown its
favorable safety profile (6–8). Data on VDZ use in PIBD patients
show that the use of VDZ is safe but that it has variable efficacy (9–
12). As the efficacy of VDZ is based on drug exposure, rather than
the administrated dose, the variation in response to VDZ may be
explained by differences in PIBD phenotype or disease activity
affecting VDZ trough levels. VDZ drug monitoring has been
described in a limited number of adult IBD patients suggesting
that albumin and body weight are factors that influence VDZ trough
levels (13). A recent meta-analysis found that 54% of patients with
IBD with secondary loss of response to VDZ may benefit from dose
optimization (14). The exact positioning of VDZ drug level moni-
toring and optimal drug levels, however, remain to be defined.
Despite these findings in adults, to date, data on VDZ trough levels
in children with IBD are lacking. We aimed to report VDZ trough
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levels over time and assess independent clinical factors that influ-
ence vedolizumab trough levels in PIBD patients.
METHODS
Study Design and Patient Management
In this retrospective study, children and adolescents aged up
to 18 years receiving VDZ therapy were studied. All patients were
included in a single tertiary hospital in the Netherlands between
2015 and 2018. Patients with UC, CD, or IBD unclassified (IBD-U)
were eligible if they had received at least 3 intravenous infusions as
induction therapy with VDZ, including those who received VDZ
combined with other immunosuppressive or immunomodulatory
medication. According to local guidelines, patients received VDZ
infusions at weeks 0, 2, and 6 (induction), and every 8 weeks
thereafter (maintenance). Children >40 kg received 300 mg VDZ
and children<40 kg received a weight-based dose of 5 mg/kg. Most
patients also received bridging therapy with oral prednisolone
(1 mg/kg, maximum of 40 mg) and were tapered with 5 mg per
week, based on physician decision and clinical response to VDZ. If
disease control during maintenance treatment was insufficient, the
interval of VDZ infusions was adjusted to every 6 or 4 weeks. The
need for VDZ treatment optimization was assessed by the physician
based on clinical data, laboratory results, and/or endoscopic evalu-
ation. Before every infusion, erythrocyte sedimentation rate (ESR),
albumin, C-reactive protein (CRP), hemoglobin, hematocrit, throm-
bocytes, and leucocytes as well as fecal calprotectin levels (Calpro
ELISA) were assessed. Clinical disease activity was scored at every
infusion by the appropriate clinical disease activity indexes, PUCAI
(Pediatric Ulcerative Colitis Activity Index) (15), or PCDAI (Pedi-
atric Crohn disease Activity Index) (16). Endoscopic evaluation was
performed when clinically indicated, before and/or after start of
VDZ treatment. Mucosal healing was defined as a Mayo endoscopic
score of zero in UC and the endoscopic absence of ileal or colonic
ulcerations in case of CD. Accordingly, active disease was defined
as the absence of mucosal healing.
Vedolizumab Trough Levels
Serum samples were collected before each infusion and
stored for retrospective determination of VDZ trough levels. Due
to batched analysis, trough levels were not available for clinical
decision-making. VDZ trough levels were determined via a quanti-
tative ELISA assay using rabbit anti-VDZ antibodies to capture
VDZ and rabbit anti-VDZ F(ab’)2 fragments, similar to the previ-
ously described method for natalizumab (Sanquin Laboratories,
Amsterdam, the Netherlands) (17). The lower limit of quantification
(LLOQ) in serum is 100 ng/mL; inter-assay precision and accuracy
are 1% to 4% and 87% to 115%, respectively. Anti-VDZ antibodies
were also measured as previously described (17). The lower limit of
detection was based on mean >3 standard deviations measured in a
panel of 30 sera from healthy donors and 45 sera from IBD patients
who were treatment-naı̈ve for VDZ.
Outcome Measures and Definitions
Primary outcome was the identification of independent
clinical factors that influence VDZ trough levels. Secondary out-
comes were therapy response, mucosal healing rates, need for
surgical intervention, and the occurrence of serious adverse events.
Therapy response was evaluated based on clinical remission and
corticosteroid-free remission (CSFR) rates. CSFR was defined as a
PUCAI <10 or PCDAI <12.5, without corticosteroid treatment or
the need of a surgical intervention.
Statistical Analysis
Continuous variables were reported as means and standard
deviations (SD) and compared by t test if normally distributed.
Continuous variables not following a normal distribution were
analyzed by the Mann-Whitney U-test and presented as median
and interquartile range (IQR). Categorical variables were presented
as absolute frequencies and percentages and compared by the x2-
test or Fisher exact test. Kaplan-Meier survival analyses were
performed to evaluate duration of VDZ therapy, time to CSFR,
and time to surgery. Three linear mixed models were constructed,
the first to identify independent predictors at baseline, before the
start of VDZ, of VDZ trough levels over time. For both models,
covariates were selected based on clinical relevance and findings in
studies with adult IBD patients. Fixed effects were days on VDZ,
IBD diagnosis (CD or UC/IBD-U), and the following parameters at
start of VDZ: age, body surface area (BSA), CRP, ESR, albumin,
and fecal calprotectin levels. The second mixed model was con-
structed to identify independent predictors during the course of
VDZ treatment of VDZ trough levels. Fixed effects included the
following time variable covariates: days on VDZ, IBD diagnosis
(CD or UC/IBD-U), BSA, dose (mg/kg), interval between infusions
in days, ESR, CRP, albumin, and fecal calprotectin levels. The third
linear mixed model was constructed to calculate mean maintenance
trough levels for patients who received VDZ infusions every
4 weeks or every 8 weeks. This interval was included as fixed
effect. In all 3 models, random slopes were tested but not included
as this did not significantly improve the model. A P-value <0.05
was considered statistically significant and no corrections for
multiple testing were performed. Calculations were performed
using IBM SPSS Statistics 24.0 (IBM Corp, Armonk, NY).
RESULTS
Patient Characteristics
Twenty-six PIBD patients were included at a median age of
12.7 years (IQR 10.1–14.5). Sixty-five percentage (n¼ 17) of
patients were diagnosed with UC/IBD-U (14 UC, 3 IBD-U) and
9 with CD (Table 1). Although UC/IBD-U patients were not
significantly younger than CD patients at the start of VDZ therapy,
their weight was significantly lower (49 vs 76 kg, P¼ 0.001). All
children had been previously exposed to either infliximab (85%),
adalimumab (4%) or both (11%). Five out of 17 UC/IBD-U patients
had a primary nonresponse to corticosteroids as well as anti-TNF.
According to the local treatment protocol, oral prednisone was used
as induction and bridging therapy in 18/26 patients (median dura-
tion 14 weeks; IQR 6–25). Four patients with a body weight below
40 kg (3 UC/IBD-U patients and 1 CD patient) received the
nonstandard weight-based dose of 5 mg/kg, the lowest being
110 mg.
Follow-up and Therapy Response
Median follow-up duration of all PIBD patients in this study
was 37 weeks (IQR 20–66). At week 14, 4/16 UC/IBD-U patients
and none of the CD patients were in CSFR. After 22 weeks, 2/6 CD
patients with available follow-up had reached CSFR (Fig. 1, Sup-
plemental Table 1, Supplemental Digital Content, http://links.lww.
com/MPG/B877). In 8 UC/IBD-U patients and 2 CD patients,
dosing interval was shortened for clinical reasons during mainte-
nance treatment. In total, 34.6% (n¼ 9) had to undergo surgery
because of therapy failure, including 6 UC/IBD-U patients and 3 CD
patients. Endoscopic evaluation was performed in 16 patients (13 UC/
IBD-U, 3 CD) after a median period of 18 weeks (IQR 14–27) on
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VDZ therapy. Twenty-five percentage was in clinical remission at the
moment of endoscopy. Mucosal healing was seen in 4/13 (31%) UC/
IBD-U patients and none of the CD patients.
Complete information on the first year of follow-up after
start of VDZ was available in 19 out of 26 patients (Fig. 2). At week
22, 88% of UC/IBD-U patients (n¼ 14) and 75% (n¼ 6) of CD
patients were still using VDZ. After 1 year, 9 of 19 (47%) PIBD
patients remained on VDZ treatment (8 UC/IBD-U, 1 CD) (Fig. 2).
In 1 CD patient, VDZ was stopped because of severe exercise
intolerance and fatigue accompanied by tachycardia, which was
possibly related to VDZ treatment.
Trough levels
In 22 PIBD patients, VDZ trough levels were measured
during induction as well as maintenance treatment, resulting in
134 trough level measurements. During induction, mean trough
levels were 32.1 mg/mL (SD 8.5) at week 2 and 29.9 mg/mL (SD
TABLE 1. Baseline characteristics
Characteristics All IBD patients (n¼ 26) CD (n¼ 9) UC/IBD-U (n¼ 17) P value
Gender, n (% male) 13 (50) 6 (67) 7 (41) 0.216
Ethnicity, n (% Caucasian) 9 (35) 3 (33) 6 (35) 0.920
Age at diagnosis, years (IQR) 12.7 (10.1–14.5) 14.0 (10.9–14.3) 12.2 (9.7–14.6) 0.634
Findings at start of vedolizumab therapy
Age, years (IQR) 15.0 (12.4–16.9) 15.5 (13.0–17.1) 13.8 (12.1–16.6) 0.458
Disease duration, years (IQR) 1.7 (1.1–2.4) 2.2 (0.9–3.3) 1.5 (1.1–2.2) 0.396
Weight, kg (IQR) 51.3 (41.7–66.9) 76.0 (69.9–77.7) 49.0 (34.8–59.2) 0.001
Body surface area, m2 (IQR) 2.3 (1.6–3.0) 2.71 (1.8–3.8) 2.2 (1.4–2.7) 0.136
PCDAI – 27.5 (15.7–37.5) –
PUCAI – – 35.0 (20.0–52.5)
Location CD, n (%) L1 – 1 (11) –
L2 – 5 (55) –
L3 – 3 (33) –
L4a/b – 4 (44) –
Behavior CD, n (%) B1 – 8 (89) –
B2 – 1 (11) –
B3 – – –
Perianal disease, n (%) 2 (8) 2 (22) –
Growth delay

, n (%) 6 (23) 2 (22) 4 (24)
Location UC/IBD-U, n (%) E1 – – –
E2 – – 6 (35)
E3 – – -
E4 – – 11 (65)
Severity UC/IBD-U, n (%) S0 – – 12
S1 – – 5
Endoscopy performed (n) 15 5 10
Mayo score 1 1
Mayo score 2 3
Mayo score 3 6
Active diseasey 4
ESR, mm/hr (IQR) (N¼ 19) 20 (11–28) 27 (14–37) 18 (9–21) 0.272
CRP, mg/L (IQR) (N¼ 24) 2.5 (0.3–16.3) 14.0 (0.3–26.5) 2.1 (0.3–11.0) 0.726
FCP, mg/g (IQR) (N¼ 10) 721 (553–825) 579 (NA) 721 (562–827) 0.711
Indication to start
vedolizumab, n (%)
IFX failure 22 (85) 6 (67) 16 (94) 0.053
Adalimumab failure 1 (4) 1 (6)
Failure IFX and Adalimumab 3 (11) 3 (33)
Reason failure anti-TNF
therapy, n (%)
Low level, ADA 3 (11) 2 (22) 1 (6) 0.809
Adequate level, loss of response 19 (73) 5 (56) 14 (82)
Low level, no ADA 2 (8) 1 (11) 1 (6)
Side effects 2 (8) 1 (11) 1 (6)
P-values in bold denote significance. P-values are calculated using a Pearson’s x2 test for categorical variables, Mann-Whitney U-test for continuous
variables and a Kruskal-Wallis Test for ordinal variables. ADA ¼ anti-drug antibodies; CD ¼ Crohn disease; IBD ¼ inflammatory bowel disease; IBD-U ¼
IBD-unclassified; IFX ¼ infliximab; IQR ¼ interquartile range; NA ¼ not available; PCDAI ¼ pediatric Crohn Disease activity index; PUCAI ¼ pediatric
ulcerative colitis disease activity index; UC ¼ ulcerative colitis.
Defined as a height z-score at diagnosis or subsequently significantly less than expected z-score; or current height z-score significantly less than height z-
score at diagnosis (reduction in height z-score since diagnosis is >0.75).
yDefined as the presence of ileal/or colonic ulcerations.
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17.8) at week 6. The lowest trough levels were measured at start of
maintenance treatment (week 14). Mean trough levels during both
induction and maintenance therapy were numerically higher in UC/
IBD-U patients than in CD patients (Fig. 3A). Mean trough levels
were, after correction for repeated measurements, 13.5 mg/mL in
UC/IBD-U patients (SD 5.6) and 9.6 mg/mL in CD patients (SD
10.8) in patients receiving VDZ every 8 weeks. If VDZ was given
every 4 weeks, mean trough levels were 28.6 mg/mL in UC/IBD-U
patients (SD 5.6) and 13.0 mg/mL in CD patients (SD 5.6) (Fig. 3B).
Antibodies to VDZ were measured in all samples, but none were
positive for antibodies to VDZ.
Factors that Influence Vedolizumab Trough
Levels
A multivariate analysis that assessed the association of
characteristics before the start of VDZ with VDZ trough levels
over time showed that higher BSA was associated with lower VDZ
trough levels (b 12.8; 95% CI 10.7 to 4.9,
P¼ 0.002). With regards to laboratory measurements, a
lower serum albumin before the start of VDZ was associated with
lower VDZ trough levels (b 1.52, 95% CI 0.42 to 2.62, P¼ 0.008),
whereas CRP, ESR, and fecal calprotectin before start of VDZ
showed no significant association with trough levels over time.
Findings from a second multivariate analysis to assess factors
during VDZ therapy associated with VDZ trough levels showed
that CD patients had significantly lower trough levels than UC/IBD-
U patients (b 15.2; 95% CI 1.1 to 29.2; P¼ 0.036, Supplemental
Table 2, Supplemental Digital Content, http://links.lww.com/MPG/
B877). Also, higher fecal calprotectin levels (b 0.009; 95% CI
0.02 to 0.003; P¼ 0.007), higher CRP (b 0.4; 95% CI 0.72
to 0.04; P¼ 0.027) and more days between infusions were
associated with lower trough levels (b 0.77; 95% CI 0.9 to
0.64; P< 0.001).
Trough Levels as Predictor of Response
Mean trough levels at 14 weeks after start of VDZ were
similar in patients who continued VDZ therapy at the end of follow-
up (as a proxy for maintenance of remission) and patients who
discontinued VDZ treatment (10.5 mg/mL, SD 7.5 vs 16.3 mg/mL,
SD 7.8, respectively; P¼ 0.166, Supplemental Table 3, Supple-
mental Digital Content, http://links.lww.com/MPG/B877). Shorten-
ing the dose interval led to increased trough levels in all patients,
including those that eventually discontinued VDZ treatment (b
0.61, 95% CI 0.77 to 0.45; P< 0.001) or were not in CSFR at
week 52 (b 0.47, 95% CI 0.62 to 0.41; P< 0.001).
DISCUSSION
In adult patients with IBD, accumulating evidence for the
role of therapeutic drug monitoring in VDZ treatment is emerging.
But other than for anti-TNF, findings are not straightforward and the
available data is limited. Most of the currently available studies are
based on data from the clinical GEMINI trials (3–5,18), and only on
few real-world cohorts (19–22). Our study, describing a real-world
cohort of anti-TNF refractory PIBD patients, is the first to report
VDZ trough levels in children with IBD.
The mean VDZ trough level in adult UC patients as measured
by the GEMINI 1 study during induction therapy (27.9 mg/mL at
week 6, n¼ 654, SD 15.5) was numerically lower than the mean
trough level we found in our pediatric cohort of UC/IBD-U patients
(31.8 mg/mL, n¼ 12, SD 14.6) (3). Numerical differences were
similar during maintenance therapy, showing levels in 77 adults that
were lower (11.2 mg/mL, SD 7.2) than those of the children in our
study (13.5 mg/mL, SD 5.6). This may be explained by the lower
median body weight of UC/IBD-U patients in our cohort compared
with the adult GEMINI study population, considering children
received the standard dosing if they were >40 kg. Trough levels
of CD patients in our cohort during induction were comparable with
those found by Sandborn et al (4) (26.8 mg/mL, SD 17.5, n¼ 827,
week 6). We, however, observed lower trough levels during main-
tenance therapy (13.0 9.1 vs 9.6 10.8 mg/mL), which could be a
result of ongoing inflammation in these patients during mainte-
nance treatment (20,21,23). Multivariate analysis in our cohort,
taking inflammatory markers, such as CRP and calprotectin into
account, showed VDZ trough levels in pediatric CD patients are
significantly lower than those in pediatric UC/IBD-U patients. This
might be because of the transmural inflammation in CD (vs more
superficial in UC), and subsequent increased disease-mediated
clearance of VDZ in the affected tissue. The VDZ mechanism of
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FIGURE 1. Clinical remission rates per time point during vedolizumab
therapy. (A) Percentage of patients with UC/IBD-U in corticosteroid-
free remission (CSFR) and clinical remission (CR) at different time
points after start of vedolizumab therapy. (B) Percentage of Crohn
disease patients in CR and CSFR at different time points after start of
vedolizumab. Percentages are based on all patients who were still
receiving vedolizumab therapy or discontinued vedolizumab therapy
at an earlier time point. Patients who were lost to follow-up were
excluded from this group. CD¼Crohn disease; CR¼ clinical remission
defined as a PUCAI<10 or a PCDAI<12.5; CSFR ¼ corticosteroid-free
remission defined as clinical remission and no use of corticosteroids at
that time point; IBD-U ¼ IBD-unclassified; UC ¼ ulcerative colitis.
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Studies based on GEMINI trial data did not show a significant
difference in trough levels between UC/IBD-U and CD patients
(18). In a population model, characterizing the pharmacokinetic
properties of VDZ, they found a similar linear clearance for UC and
CD patients (13,17).
In our cohort, only a small number of UC patients and none
of the CD patients were in CSFR 14 weeks after the start of VDZ
therapy. Despite the relatively long duration of corticosteroid use, it
seems that CD patients are less likely to respond to VDZ and need a
longer duration on VDZ therapy in order to improve clinically.
These findings are in line with findings in another PIBD cohort.
They showed that after a median follow-up of 24 weeks, UC
patients were more likely to be in remission (39%) than CD patients
(24%) (9). The remission rates reported in adult studies are higher
than the rates observed in the children in our cohort (17,24), which
may be explained by inclusion of anti-TNF refractory PIBD patients
only, whereas this was not the case in the adult studies. This
is supported by studies showing significantly better outcomes in
anti-TNF-naı̈ve IBD patients (25–27). Although an accelerated
clearance because of immunogenicity is a frequently reported
n=26 
9 CD, 17 UC/IBD-U
Transfer to adult care within 
first year (n=3)
Not reached 1 year follow up yet 
(n=4)
1 year follow up informaon 
available (n=19)
CD (n=6) UC/IBD-U (n=13)
Sll on VDZ at 54 weeks (n=1) Sll on VDZ at 54 week (n=8)
Disconnued due to ongoing 
inflammaon (n=3)
Disconnued based on own 
choice (n=1)
Disconnued due to ongoing 
inflammaon (n=4)
Disconnued based on own 
choice (n=1)
Disconnued due to side 
effects (n=1)
FIGURE 2. Flow chart of included patients. CD ¼ Crohn disease; IBD-U ¼ IBD-unclassified; UC ¼ ulcerative colitis; VDZ ¼ vedolizumab.














































FIGURE 3. Mean vedolizumab trough levels. (A) Mean vedolizumab trough levels  standard deviation (SD) per time point during induction
therapy. (B) Mean vedolizumab trough levels during maintenance therapy (weeks 14–176). Depicted for patients with normal dosing interval
(every 8 weeks) and intensified dosing interval (every 4 weeks). The difference in trough levels following the different dosing intervals was
evaluated for each diagnosis. P values were considered significant if <0.05.
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explanation for loss of response to anti-TNF, our data do not suggest
that nonresponse or loss of response to VDZ can be explained by the
formation of antibodies to VDZ (28). This is consistent with studies
in adults that indicate immunogenicity to occur in <5% of cases
(17,29).
Accumulating evidence of an exposure-efficacy relationship
is emerging in adult IBD patients (18–21). Ungaro et al (23)
included 258 IBD patients, and found significantly higher VDZ
concentrations if patients were in clinical, biochemical, and endo-
scopic remission. Lower trough levels could very well be a reflec-
tion of disease activity and increased clearance (13). This is in line
with findings in our cohort showing that higher CRP and fecal
calprotectin levels are associated with lower trough levels. On the
contrary, in another cohort of 73 IBD patients, VDZ trough levels
were not associated with clinical, biological, or endoscopic out-
comes (30). A systematic review and meta-analysis by Singh et al
(31) showed that in UC patients, VDZ trough levels are significantly
higher in patients that are in clinical and endoscopic remission;
however, for CD patients, no significant differences were found.
Due to the heterogeneity in the available adult studies and their
findings, optimal therapeutic ranges for VDZ have not yet been
determined (32).
Our findings indicate that there is an important role for
therapeutic drug monitoring of VDZ in this pediatric population
that has very limited treatment options left. Following a multivari-
ate approach to repeated measures in our cohort, we found IBD
diagnosis to be a significant predictor of trough levels. The finding
of CD diagnosis as an independent predictor of lower trough levels
in our cohort indicates that pediatric CD patients may profit from
therapeutic drug monitoring and higher dosing of VDZ. Our
statistical analysis did not result in a significant difference in trough
levels between patients who were in CSFR and those who were not,
which is likely to be because of the number of patients included in
this study.
There are limitations to this study, of which some can be
addressed in future research. The most important limitation being
the retrospective design of the study and the small number of
included PIBD patients. A larger cohort is needed to assess the
exposure-efficacy relationship, but because of the off-label use of
VDZ in this pediatric population studies in a large group of PIBD
patients are extremely challenging. Importantly, as we collected a
large number of through levels during follow-up, the small cohort
did not limit our analysis of factors that influence VDZ trough
levels. A second limitation is the long duration of corticosteroid
treatment as induction and bridging therapy, which may affect the
interpretation of the effectiveness of VDZ therapy.
To our best knowledge, we are the first to present data on
VDZ trough levels in children with IBD. We hereby show that VDZ
trough levels are comparable to those in adults and provide insight
in which clinical factors influence VDZ trough levels in children
with IBD. A pharmacokinetic/pharmacodynamic model in PIBD
patients, including patients using lower doses of VDZ, would
improve our knowledge on clearance of VDZ, as well as the relation
between drug levels and response in these children. Larger pro-
spective cohorts are needed to validate our findings and optimize
dosing and treatment guidelines regarding VDZ therapy in
PIBD patients.
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